ALXO Q3 2024 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$33M

Net Income

-$31M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$186M

Total Liabilities

$49M

Stockholders' Equity

$137M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$33M	-$53M	+38.9%
Net Income	-$31M	-$51M	+39.8%